EP1772142A3 - Composés organiques - Google Patents

Composés organiques Download PDF

Info

Publication number
EP1772142A3
EP1772142A3 EP07100048A EP07100048A EP1772142A3 EP 1772142 A3 EP1772142 A3 EP 1772142A3 EP 07100048 A EP07100048 A EP 07100048A EP 07100048 A EP07100048 A EP 07100048A EP 1772142 A3 EP1772142 A3 EP 1772142A3
Authority
EP
European Patent Office
Prior art keywords
organic compounds
corticosteroid
medicament
inflammatory
sequential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07100048A
Other languages
German (de)
English (en)
Other versions
EP1772142A2 (fr
Inventor
Bernard Cuenoud
Robin Alec Fairhurst
Nicholas Lowther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of EP1772142A2 publication Critical patent/EP1772142A2/fr
Publication of EP1772142A3 publication Critical patent/EP1772142A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP07100048A 2000-12-04 2001-12-03 Composés organiques Withdrawn EP1772142A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0029562.6A GB0029562D0 (en) 2000-12-04 2000-12-04 Organic compounds
EP01999366A EP1341542B1 (fr) 2000-12-04 2001-12-03 Dérivés indanyl pour le traitement de maladies des voies respiratoires

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP01999366A Division EP1341542B1 (fr) 2000-12-04 2001-12-03 Dérivés indanyl pour le traitement de maladies des voies respiratoires
EP01999366.6 Division 2001-12-03

Publications (2)

Publication Number Publication Date
EP1772142A2 EP1772142A2 (fr) 2007-04-11
EP1772142A3 true EP1772142A3 (fr) 2011-09-14

Family

ID=9904414

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07100048A Withdrawn EP1772142A3 (fr) 2000-12-04 2001-12-03 Composés organiques
EP01999366A Expired - Lifetime EP1341542B1 (fr) 2000-12-04 2001-12-03 Dérivés indanyl pour le traitement de maladies des voies respiratoires

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01999366A Expired - Lifetime EP1341542B1 (fr) 2000-12-04 2001-12-03 Dérivés indanyl pour le traitement de maladies des voies respiratoires

Country Status (28)

Country Link
US (5) US6800643B2 (fr)
EP (2) EP1772142A3 (fr)
JP (2) JP2004514739A (fr)
KR (1) KR100523541B1 (fr)
CN (1) CN1212119C (fr)
AT (1) ATE361077T1 (fr)
AU (2) AU1708202A (fr)
BR (1) BRPI0115910B8 (fr)
CA (1) CA2427282C (fr)
CY (1) CY1106727T1 (fr)
CZ (1) CZ304294B6 (fr)
DE (1) DE60128258T2 (fr)
DK (1) DK1341542T3 (fr)
EC (1) ECSP034620A (fr)
ES (1) ES2284732T3 (fr)
GB (1) GB0029562D0 (fr)
HK (1) HK1059564A1 (fr)
HU (1) HU229552B1 (fr)
IL (2) IL155709A0 (fr)
MX (1) MXPA03004976A (fr)
NO (1) NO325692B1 (fr)
NZ (1) NZ525731A (fr)
PL (1) PL204002B1 (fr)
PT (1) PT1341542E (fr)
RU (1) RU2292890C2 (fr)
SK (1) SK287331B6 (fr)
WO (1) WO2002045703A2 (fr)
ZA (1) ZA200303399B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
US20040146509A1 (en) * 2002-07-25 2004-07-29 Zhihe Li Methods for improvement of lung function using TGF-beta inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
TWI324151B (en) * 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
EP1613315B1 (fr) 2003-04-04 2009-01-21 Novartis AG Derives de quinoline-2-one permettant de traiter des maladies des voies respiratoires
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
US7820676B2 (en) 2004-08-23 2010-10-26 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
KR100666220B1 (ko) * 2005-01-31 2007-01-09 영남대학교 산학협력단 구내염 치료용 분사제 조성물
MX2007012084A (es) * 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
CA2621806C (fr) 2005-09-14 2016-08-02 Mannkind Corporation Procede de preparation de medicaments fonde sur l'accroissement de l'affinite des surfaces de microparticules cristallines pour des principes actifs
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
WO2007075963A2 (fr) * 2005-12-20 2007-07-05 Tika Läkemedel Ab Systèmes et méthodes d'administration de corticostéroïdes
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
US20070225233A1 (en) * 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
EP1878722A1 (fr) * 2006-07-13 2008-01-16 Novartis AG Dérivés de quinolinone et leur compositions pharmaceutiques
EP2044025B1 (fr) * 2006-06-30 2012-10-03 Novartis AG Dérivés de quinolines et compositions pharmaceutiques de ces dérivés
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3086027C (fr) 2008-06-13 2022-05-17 Mannkind Corporation Inhalateur de poudre seche et systeme d'administration de medicament
RU2470681C2 (ru) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (fr) 2009-03-11 2017-03-01 MannKind Corporation Appareil, système et procédé de mesure de résistance d'un inhalateur
BRPI1011229B8 (pt) 2009-05-29 2021-05-25 Pearl Therapeutics Inc co-suspensão dispensável a partir de um inalador de dose medida compreendendo propelente, partículas de agente ativo e partículas em suspensão
KR20210027546A (ko) 2009-06-12 2021-03-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
KR100940388B1 (ko) * 2009-07-01 2010-02-02 유병덕 스크류탈수기 및 이를 포함하는 유기성폐기물 건조장치
WO2011056889A1 (fr) 2009-11-03 2011-05-12 Mannkind Corporation Appareil et méthode de simulation d'efforts d'inhalation
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
KR20180091120A (ko) * 2010-07-16 2018-08-14 시플라 리미티드 Ｒ　(＋)　부데소나이드 및 1종 이상의 기관지확장제를 포함하는 약학 조성물
WO2012049444A1 (fr) 2010-10-12 2012-04-19 Cipla Limited Composition pharmaceutique
EP2694402B1 (fr) 2011-04-01 2017-03-22 MannKind Corporation Emballage coque pour cartouches pharmaceutiques
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
CN102247380A (zh) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 一种以布地奈德与茚达特罗为活性成分的复方制剂
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
WO2013132514A2 (fr) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan Nouveau procédé de préparation de (r)-5-[2-[(5, 6-diéthyl-2, 3-dihydro-1h-indèn-2-yl) amino]-1-hydroxyéthyl]-8-hydroxy quinoléin-2(1h)-one
WO2014008639A1 (fr) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 Procédé de préparation d'indacatérol
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
WO2014044288A1 (fr) 2012-09-21 2014-03-27 Crystal Pharma Sa Procédés de préparation d'indacatérol et de ses sels pharmaceutiquement acceptables
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
WO2015021064A1 (fr) 2013-08-05 2015-02-12 Mannkind Corporation Appareil d'insufflation et procédés
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
ITUB20153978A1 (it) * 2015-09-28 2017-03-28 Laboratorio Chimico Int S P A Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi.
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN106831445B (zh) * 2016-11-22 2019-01-22 斯芬克司药物研发（天津）股份有限公司 一种茚基胺化合物的制备方法
CN110229078A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 一种茚达特罗起始原料开环杂质的制备
CN114751857A (zh) * 2022-04-29 2022-07-15 梯尔希（南京）药物研发有限公司 一种茚达特罗杂质的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075114A1 (fr) * 1999-06-04 2000-12-14 Novartis Ag Agonistes du recepteur beta 2-adrenergique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
WO1993018007A1 (fr) * 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
GB9501286D0 (en) * 1995-01-24 1995-03-15 Ciba Geigy Ag Pharmaceutical compositions and preparations thereof
EP0761216B1 (fr) * 1995-08-16 2003-11-12 Huntington Medical Research Institutes Compositions à base de rhodamine 123 destinées au traitement du cancer de la prostate
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
SG72727A1 (en) 1996-02-19 2000-05-23 Kissei Pharmaceutical 3,4-Disubstituted phenylethanolaminotetralincarboxamide derivatives
GB9610122D0 (en) * 1996-05-15 1996-07-24 Reckitt & Colmann Prod Ltd Organic compositions
CA2296104A1 (fr) * 1997-07-03 1999-01-14 Asahi Kasei Kogyo Kabushiki Kaisha Nouveaux composes tricycliques presentant des noyaux satures et compositions medicinales les contenant
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
US6664235B1 (en) * 1999-08-20 2003-12-16 Riken Medicaments comprising sialic acid derivatives as active ingredients
CA2417973A1 (fr) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Preparations de mometasone et bronchodilatateur pour administration par voie pulmonaire
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075114A1 (fr) * 1999-06-04 2000-12-14 Novartis Ag Agonistes du recepteur beta 2-adrenergique

Also Published As

Publication number Publication date
KR100523541B1 (ko) 2005-10-25
CA2427282A1 (fr) 2002-06-13
KR20030048065A (ko) 2003-06-18
HK1059564A1 (en) 2004-07-09
AU1708202A (en) 2002-06-18
PL204002B1 (pl) 2009-12-31
MXPA03004976A (es) 2003-09-05
EP1341542B1 (fr) 2007-05-02
US20120108555A1 (en) 2012-05-03
PT1341542E (pt) 2007-08-01
RU2292890C2 (ru) 2007-02-10
DE60128258T2 (de) 2007-12-27
US20040038951A1 (en) 2004-02-26
WO2002045703A2 (fr) 2002-06-13
US7008951B2 (en) 2006-03-07
CZ304294B6 (cs) 2014-02-19
IL155709A (en) 2008-11-26
NZ525731A (en) 2004-11-26
NO20032510D0 (no) 2003-06-03
BR0115910A (pt) 2004-01-20
IL155709A0 (en) 2003-11-23
BRPI0115910B1 (pt) 2019-12-31
ATE361077T1 (de) 2007-05-15
CN1212119C (zh) 2005-07-27
US20060052352A1 (en) 2006-03-09
DE60128258D1 (de) 2007-06-14
ZA200303399B (en) 2004-04-23
DK1341542T3 (da) 2007-09-03
PL362443A1 (en) 2004-11-02
ECSP034620A (es) 2003-06-25
JP2007302684A (ja) 2007-11-22
CA2427282C (fr) 2010-10-19
HUP0302571A2 (hu) 2003-11-28
EP1772142A2 (fr) 2007-04-11
EP1341542A2 (fr) 2003-09-10
CZ20031537A3 (cs) 2003-10-15
NO20032510L (no) 2003-06-03
NO325692B1 (no) 2008-07-07
US7622484B2 (en) 2009-11-24
CN1477963A (zh) 2004-02-25
ES2284732T3 (es) 2007-11-16
SK287331B6 (sk) 2010-07-07
HUP0302571A3 (en) 2005-05-30
AU2002217082B2 (en) 2005-04-07
BRPI0115910B8 (pt) 2021-05-25
CY1106727T1 (el) 2012-05-23
US20100068288A1 (en) 2010-03-18
US6800643B2 (en) 2004-10-05
WO2002045703A3 (fr) 2003-03-13
GB0029562D0 (en) 2001-01-17
HU229552B1 (en) 2014-01-28
JP2004514739A (ja) 2004-05-20
US20050009795A1 (en) 2005-01-13
SK6502003A3 (en) 2003-12-02
RU2003119549A (ru) 2005-02-10

Similar Documents

Publication Publication Date Title
EP1772142A3 (fr) Composés organiques
CA2360248A1 (fr) Combinaisons de formoterol et de sel de tiotropium
EP1159964A3 (fr) Compositions et methodes pour stimuler la motilité gastrointestinale
EP1797878A3 (fr) Dérivés de benzothiazoles
GB9904919D0 (en) Organic compounds
EP2228064A3 (fr) Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique
WO2007057221A3 (fr) Composes organiques
EP2036902A3 (fr) Derives de l'uree actifs comme antagonistes des recepteurs vanilloides
EP2269609A3 (fr) Traitement des maladiees neurodégénératives et le cancer du cerveau avec l'acide hydroxamique subéroylanilide (le SAHA)
EP1659111A3 (fr) Derives de piperidine utiles comme des antagonistes de ccr5
MY148125A (en) Compounds
HK1096399A1 (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-
EP2210892A3 (fr) Composés actifs neurologiquement
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
EP2452684A3 (fr) Micelles
WO2002088100A3 (fr) 3-piperidinopropiophenones dopees et produits pharmaceutiques contenant ces composes
EP1431286A3 (fr) Derives du prodigiosine destines au traitement du cancer et des maladies virales
EP1175900A3 (fr) Utilisation de secretagogues d'hormone de croissance pour amélioration de l'état de sante fonctionelle
CA2389032A1 (fr) Agents de prevention ou de traitement de maladies inflammatoires de l'intestin
EP1253139A3 (fr) Fullerènes multioligoanilinés
CA2370501A1 (fr) Compositions medicinales destinees au traitement de l'uropathie inferieur
EP2216025A3 (fr) Utilisation de derives d'amide d'acylaminoalkenylene dans le côlon irritable et la dyspepsie fonctionelle
EP1413302A3 (fr) Guanidines substitutées et utilisation pour le traitement de douleurs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1341542

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LOWTHER, NICHOLAS

Inventor name: FAIRHURST, ROBIN ALEC

Inventor name: CUENOUD, BERNARD

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1108364

Country of ref document: HK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20110805BHEP

Ipc: A61K 31/575 20060101AFI20110805BHEP

17P Request for examination filed

Effective date: 20120314

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AXX Extension fees paid

Extension state: SI

Payment date: 20120314

Extension state: RO

Payment date: 20120314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120315

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1108364

Country of ref document: HK